Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience

Turunc, Volkan; Ari, Elif; Guven, Bahtisen; Tabendeh, Babek; Yildiz, Aladdin

doi:10.1016/j.transproceed.2019.01.149

Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience

Copy For Citation

Turunc V., Ari E., Guven B., Tabendeh B., Yildiz A.

TRANSPLANTATION PROCEEDINGS, vol.51, no.7, pp.2308-2311, 2019 (SCI-Expanded)

Publication Type: Article / Article
Volume: 51 Issue: 7
Publication Date: 2019
Doi Number: 10.1016/j.transproceed.2019.01.149
Journal Name: TRANSPLANTATION PROCEEDINGS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2308-2311
Istanbul University Affiliated: Yes

Abstract

Background. This study aimed to determine whether de novo, prolonged-release tacrolimus- (PR-tacro) based immunosuppressive regimen affected graft and patient survival when compared to an immediate-release, twice-daily, tacrolimus- (IR-tacro) based regimen in kidney transplant recipients. We also aimed to determine the difference between the frequency of side effects, including diabetes control, in study groups.